China's BioKangtai and Chile sign cooperation agreement for Phase III clinical trial of COVID-19 vaccine

2021-05-25 13:30:00

China's Shenzhen Kangtai Biological Products Co., Ltd. (BioKangtai) held a signing ceremony online with Chile's Advanced Medical Systems And Investments S.A., the University of Chile, and other institutions on Monday, May 24.

Several parties reached agreements on Phase III clinical trials and product procurement for BioKangtai's inactivated COVID-19 vaccine in Chile in the virtual ceremony.

BioKangtai announced on May 14 that its COVID-19 vaccine was approved for emergency use in China.

At present, BioKangtai has started Phase III clinical trials of the COVID-19 vaccine in many countries worldwide.

Chile Vaccine COVID Chinese Company

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Tencent Holdings repurchased 3.93 million shares for HK$1.5 billion on January 7
                            2025-01-07

                                    Ireland recorded a 12.8 billion euro fiscal surplus last year due to the "Apple tax" ruling
                            2025-01-07

                                    Ministry of Industry and Information Technology: Promoting technical verification of 10G optical network and artificial intelligence integration
                            2025-01-07

                                    Tencent's major shareholder Prosus reduced its stake in Tencent Holdings from 24.01% to 23.99% on January 6.
                            2025-01-07

                                    U.S. chip stocks rose before the market opened, with Nvidia up 0.6%
                            2025-01-07